中關村(000931.SZ):擬調整發展戰略 由以“醫藥大健康為核心”的再聚焦、變更為創新型醫藥產業集團
格隆匯8月13日丨中關村(000931.SZ)公佈,公司結合自身和外部環境情況,通過客觀分析和深入研究,擬對公司發展戰略及相關業務發展策略進行調整,具體如下:
以創新為驅動,以政策和需求為導向,整合內外部資源,以現有醫藥業務為基礎,通過激活沉澱品種、產品線自研擴充,構建原料藥到製劑一體化的有競爭力的生產模式,穩步提升現有業務規模,強化在心血管、口腔、消化、婦科和麻精等多個領域的市場競爭力。同時,積極探索生物製藥新領域,全力推動創新型藥物的發展,打造多個產品集羣,更進一步地提升市場競爭力。由以“醫藥大健康為核心”的公司再聚焦,變更為創新型醫藥產業集團。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.